Patent SG-11201810290W-A (SG)
Title: Combination therapies with farnesoid x receptor (fxr) modulators
Inventor: MOHAN RAJU
IPC: A61K31/55
Filed: 2017-05-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 111010101111101011111 0 011111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/205684 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: A61K 31/55 (2006.01) A61K 45/06 (2006.01) Published: — with international search report (Art. 2 1 (3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/034564 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 25 May 2017 (25.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,482 25 May 2016 (25.05.2016) US 62/341,487 25 May 2016 (25.05.2016) US (71) Applicant: AKARNA THERAPEUTICS, LTD. [GB/GB]; St. John's Innovation Centre, Cowley Road, Cambridge CB4 OWS (GB). (72) Inventor; and (71) Applicant: PRATT, Benjamin, Anthony [US/US]; 1057 Guadalajara Drive, Encinitas, CA 92024 (US). (72) Inventor: MOHAN, Raju; 3125 Caminito Ricardo, Encinitas, CA 92024 (US). (74) Agent: PINO, Mark, J.; Mintz Levin Cohn Ferris Glovsky And Popeo, PC, 701 Pennsylvania Avenue, Nw, Suite 900, Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). 7r GC (54) Title: COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS kr) © (57) : Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-adminis- tering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 IN antagonist, ASK1 inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, © diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or N GLP-1 agonist, or a combination thereof. C